{{Drugbox
| Verifiedfields = 
| Watchedfields = 
| verifiedrevid = 
| IUPAC_name = (8S,9S,11S,13S,14S,17R)-17-ethynyl-11-methoxy-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-3,17-diol
| image = Moxestrol_structure.svg
| width = 250

<!--Clinical data-->
| tradename = Surestryl
| pregnancy_category = X (Contraindicated)
| legal_status = Rx-only
| routes_of_administration = [[Oral administration|Oral]]

<!--Pharmacokinetic data-->
| bioavailability = 33%<ref name="SalmonCoussediere1983" />
| protein_bound = Minimal<ref name="SalmonCoussediere1983" />
| metabolism = 
| elimination_half-life = 8.2 hours<ref name="SalmonCoussediere1983">{{cite journal|last1=Salmon|first1=J.|last2=Coussediere|first2=D.|last3=Cousty|first3=C.|last4=Raynaud|first4=J.P.|title=Pharmacokinetics and metabolism of moxestrol in animals—rat, dog and monkey|journal=Journal of Steroid Biochemistry|volume=19|issue=2|year=1983|pages=1223–1234|issn=0022-4731|doi=10.1016/0022-4731(83)90421-1}}</ref>
| excretion = 

<!--Identifiers-->
| CAS_number_Ref = 
| CAS_number = 34816-55-2
| CAS_supplemental = 
| ATC_prefix = G03
| ATC_suffix = CB04
| PubChem = 11954041
| DrugBank_Ref = 
| DrugBank = 
| ChemSpiderID_Ref = 
| ChemSpiderID = 10128336

<!--Chemical data-->
| C=21 | H=26 | O=3
| molecular_weight = 326.42934 g/mol
| smiles = CC12CC(C3C(C1CCC2(C#C)O)CCC4=C3C=CC(=C4)O)OC
| StdInChI = 1S/C21H26O3/c1-4-21(23)10-9-17-16-7-5-13-11-14(22)6-8-15(13)19(16)18(24-3)12-20(17,21)2/h1,6,8,11,16-19,22-23H,5,7,9-10,12H2,2-3H3/t16-,17-,18-,19+,20-,21-/m0/s1
| StdInChIKey = MTMZZIPTQITGCY-OLGWUGKESA-N
| synonyms = R-2858, RU-2858, NSC-118191
}}

'''Moxestrol''' ([[International Nonproprietary Name|INN]]) (brand name '''Surestryl'''), also known as '''11β-methoxy-17α-ethynyl-1,3,5(10)-estratriene-3,17β-diol''' or as '''11β-methoxy-17α-ethynylestradiol''', is a [[Organic compound#Synthetic compounds|synthetic]], [[steroid]]al [[estrogen]] that is or was used in [[Europe]] for the treatment of [[menopause|menopausal]] symptoms.<ref name="Elks2014">{{cite book|author=J. Elks|title=The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies|url=https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA841|date=14 November 2014|publisher=Springer|isbn=978-1-4757-2085-3|pages=841–}}</ref><ref name="MortonMorton1999">{{cite book|author1=Dr. Ian Morton|author2=I.K. Morton|author3=Judith M. Hall|title=Concise Dictionary of Pharmacological Agents: Properties and Synonyms|url=https://books.google.com/books?id=mqaOMOtk61IC&pg=PA186|date=31 October 1999|publisher=Springer Science & Business Media|isbn=978-0-7514-0499-9|pages=186–}}</ref><ref name="LiNandi2012">{{cite book|author1=Jonathan J. Li|author2=Satyabrata Nandi|author3=Sara A. Li|title=Hormonal Carcinogenesis: Proceedings of the First International Symposium|url=https://books.google.com/books?id=oPgxBwAAQBAJ&pg=PT184|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-1-4613-9208-8|pages=184–}}</ref><ref name="Nunn1992">{{cite book|author=Adrain D. Nunn|title=Radiopharmaceuticals: Chemistry and Pharmacology|url=https://books.google.com/books?id=iWrTdGUbjzEC&pg=PA342|date=19 June 1992|publisher=CRC Press|isbn=978-0-8247-8624-3|pages=342–}}</ref> It is the 11β-methoxy derivative of [[ethinylestradiol]], and is one of the most [[potency (pharmacology)|potent]] estrogens known, being some 10–100 times more potent than [[estradiol]] and about 5-fold more potent than ethinylestradiol.<ref name="LiNandi2012" /><ref name="Nunn1992" /> The very high potency of moxestrol has been attributed to its high [[affinity (pharmacology)|affinity]] for the [[estrogen receptor]] (ER), its negligible [[plasma protein binding|plasma binding]] to [[sex hormone binding globulin]] and low binding to [[serum albumin]],<ref name="SalmonCoussediere1983" /> and its lower relative rate of [[metabolization]].<ref name="LiNandi2012" /><ref name="Nunn1992" /> In contrast to estradiol, which has roughly the same affinity for both ERs (K<sub>i</sub> = 0.12 nM and 0.15 nM, respectively), moxestrol possesses several-fold selectivity for [[estrogen receptor alpha|ERα]] (K<sub>i</sub> = 0.50 nM) over [[estrogen receptor beta|ERβ]] (K<sub>i</sub> = 2.6 nM).<ref name="pmid16452668">{{cite journal | vauthors = Lund TD, Hinds LR, Handa RJ | title = The androgen 5alpha-dihydrotestosterone and its metabolite 5alpha-androstan-3beta, 17beta-diol inhibit the hypothalamo-pituitary-adrenal response to stress by acting through estrogen receptor beta-expressing neurons in the hypothalamus | journal = J. Neurosci. | volume = 26 | issue = 5 | pages = 1448–56 | year = 2006 | pmid = 16452668 | doi = 10.1523/JNEUROSCI.3777-05.2006 | url = }}</ref>

==See also==
* [[Ethinylestradiol sulfonate]]
* [[Mestranol]]
* [[Quinestrol]]

==References==
{{Reflist|2}}


{{Estrogens and antiestrogens}}
{{Estrogen receptor modulators}}

[[Category:Alkynes]]
[[Category:Estranes]]
[[Category:Synthetic estrogens]]


{{genito-urinary-drug-stub}}
{{steroid-stub}}